^
BIOMARKER:

EGFR exon 20 insertion

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR exon 20 insertion
NSCLC
osimertinib
Sensitive: C2 – Inclusion Criteria
Lung Cancer - 1 week - (New C3)
EGFR exon 20 insertion
NSCLC
HM 78136B
Sensitive: C2 – Inclusion Criteria
Front Oncol - 3 weeks - (New C4)
EGFR exon 20 insertion
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 3 weeks - (New C3)
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
amivantamab-vmjw
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
afatinib
Sensitive: B - Late Trials
EGFR exon 20 insertion
NSCLC
CLN-081
Sensitive: B - Late Trials
EGFR exon 20 insertion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR exon 20 insertion
NSCLC
DZD9008
Sensitive: B - Late Trials
EGFR exon 20 insertion
NSCLC
cetuximab + afatinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 20 insertion
Solid Tumor
BDTX-189
Sensitive: C2 – Inclusion Criteria
EGFR exon 20 insertion
NSCLC
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
EGFR exon 20 insertion
NSCLC
erlotinib
Resistant: C2 – Inclusion Criteria
EGFR exon 20 insertion
NSCLC
furmonertinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 20 insertion
NSCLC
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 20 insertion
NSCLC
aumolertinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 20 insertion
NSCLC
cisplatin + pemetrexed
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
gefitinib
Resistant: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
PD1 inhibitor
Resistant: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
Platinum alkylating agent
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
KN046
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
pembrolizumab
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
anlotinib + sintilimab
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
NSCLC
Angiogenesis inhibitor
Sensitive: C3 – Early Trials
EGFR exon 20 insertion
LUAD
bevacizumab
Sensitive: C4 – Case Studies
EGFR exon 20 insertion
LUAD
osimertinib
Resistant: C4 – Case Studies
EGFR exon 20 insertion
NSCLC
dacomitinib
Sensitive: C4 – Case Studies
EGFR exon 20 insertion
Thymic Carcinoma
anlotinib
Sensitive: C4 – Case Studies
EGFR exon 20 insertion
LUAD
bevacizumab + cetuximab
Sensitive: C4 – Case Studies
EGFR exon 20 insertion
Solid Tumor
BLU-451
Sensitive: D – Preclinical
EGFR exon 20 insertion
NSCLC
GB263T
Sensitive: D – Preclinical